Search results (251)
« Back to NewsOchre Bio outgrows the BioEscalator
27 October 2022
With Ochre Bio's chemistry laboratory housed at The Oxford Science Park, it was a no-brainer for the company to move over to the park when it outgrew the BioEscalator.
Mental health in the SME community
9 October 2022
Starting up your own business is challenging at the best of times; business plans, funding, licensing and IP are just a few of the hurdles founders face. In addition to the global pandemic and the current financial crisis in the UK, SMEs are under more pressure than ever.
The BioEscalator bids farewell to Nucleome Therapeutics
26 September 2022
Nucleome Therapeutics has outgrown its space at the BioEscalator and moved to pastures new. The company will continue its growth journey at The Oxford Science Park.
OSPT selected by INCATEurope as one of the 6 new ventures to receive Stage I support
23 August 2022
This new funding will help OSPT refine its regulatory strategy.
PepGen graduates from the BioEscalator
31 July 2022
PepGen is the last of the original cohort of companies that moved into the BioEscalator when it first opened. The new PepGen headquarters in Boston, USA, will manage late-stage preclinical testing and clinical and regulatory functions.
BioEscalator Pitch Battle 2022
11 July 2022
Infinitopes win the battle with an excellent presentation from CEO Jonathan Kwok on how the company is pushing the boundaries of science and medicine to identify hidden tumour targets to create high-efficiency vaccines.
The BioEscalator holds its first mini supplier show
10 July 2022
The show hosted four laboratory equipment and services companies: Olink, Stemcell, Analytik-Jena UK, and Tecan.
Fun in the sun at BioEscalator's Party in the Park
6 July 2022
The BioEscalator team and resident companies made their way to South Park, Oxford, today to enjoy well-deserved downtime at the BioEscalator's first Party in the Park.
Introducing Theraport
30 June 2022
Winner of OUBT's Biohackathon 2022, part of the Oxford Catalyse Programme, Theraport join the BioEscalator community for three months.
Introducing Oxford Cancer Analytics
21 June 2022
OXcan, short for Oxford Cancer Analytics, uses machine learning techniques combined with cutting-edge liquid biopsy techniques, to search for stage one lung cancer biomarkers.
Introducing Evolvere Biosciences
12 June 2022
A platform to develop biologic therapeutics that outsmart the evolution of antibiotic resistance to save millions of lives.
Tours and tenant talks at the BioEscalator open afternoon
24 May 2022
The event's purpose was to raise awareness of the BioEscalator and showcase the incredible science happening within its walls.
CyanoCapture moves on from the BioEscalator
15 May 2022
The company has moved into the newly refurbished Hayakawa Building at the Oxford Science Park.
Ochre Bio has announced the launch of its ‘Liver ICU’ in the US to Evaluate Effects of RNA Therapies on Human Liver Performance
10 May 2022
This research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines.
Nucleome Therapeutics shortlisted as a finalist for the 2022 Oxfordshire Business Awards
9 May 2022
Nucleome Therapeutics, a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease with precision medicines, is in the running to receive the Oxfordshire LEP New Business Award.
PepGen Announces Pricing of Initial Public Offering
4 May 2022
The shares are expected to begin trading on the Nasdaq Global Select Market on 6 May 2022 under the symbol “PEPG.” The offering is expected to close on 10 May 2022, subject to the satisfaction of customary closing conditions.
Exogene Raises $2M (£1.5M) for Its AI Platform to Discover Cell Therapies for Cancer
27 April 2022
Exogene, a biotech company discovering novel T-cell receptor-based cell therapies, has raised $2M in funding to develop its artificial intelligence (AI) platform for T-cell receptor discovery.
Kyttaro enters Worldwide Exclusive Licensing Agreement with Eli Lilly for Antibody Therapeutic Programme
10 April 2022
The company plans to develop Lilly’s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for the treatment of atherosclerotic cardiovascular disease and potentially other conditions.
PepGen announced its first participant dosed in a Phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular Dystrophy
5 April 2022
Initiation of Phase 1 Study marks PepGen’s transition to a clinical-stage company. This Phase 1 Healthy Normal Volunteer (HNV) study will evaluate safety and tolerability as the primary objective. It will begin to evaluate the delivery and target engagement of PGN-EDO51 to enable subsequent patient trials.
Oxford Silk Phage Technologies awarded three consecutive grants from OxLEP’s ISfB programme
30 March 2022
OSPT has been awarded £680K to advance its disruptive antibacterial technology.